Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Protagonist Therapeutics Inc shares valued at $1,162,280 were sold by MOLINA ARTURO MD on Nov 27 ’24. At $44.70 per share, MOLINA ARTURO MD sold 26,000 shares. The insider’s holdings dropped to 46,444 shares worth approximately $1.94 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, MOLINA ARTURO MD sold 5,529 shares, netting a total of over 252,122 in proceeds. Following the sale of shares at $45.60 each, the insider now holds 46,444 shares.
Before that, Gupta Suneel had sold 103,437 shares from its account. In a trade valued at $4,762,239, the Chief Development Officer traded Protagonist Therapeutics Inc shares for $46.04 each. Upon closing the transaction, the insider’s holdings decreased to 103,437 shares, worth approximately $10.68 million.
As published in their initiating research note from Wedbush on November 05, 2024, Protagonist Therapeutics Inc [PTGX] has been an Outperform and the price target has been revised to $58. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in late September. As of September 09, 2024, Truist has initiated its “Buy” rating for PTGX. Earlier on October 30, 2023, CapitalOne initiated its rating. Their recommendation was “an Overweight” for PTGX stock.
Analyzing PTGX Stock Performance
During the last five days, there has been a drop of approximately -7.27%. Over the course of the year, Protagonist Therapeutics Inc shares have jumped approximately 81.77%. Shares of the company reached a 52-week high of $48.89 on 10/28/24 and a 52-week low of $21.43 on 01/05/24. A 50-day SMA is recorded $44.81, while a 200-day SMA reached $36.52. Nevertheless, trading volume fell to 0.81 million shares from 0.34 million shares the previous day.
Support And Resistance Levels for Protagonist Therapeutics Inc (PTGX)
According to the 24-hour chart, there is a support level at 40.57, which, if violated, would cause prices to drop to 39.46. In the upper region, resistance lies at 42.92. The next price resistance is at 44.16. RSI (Relative Strength Index) is 43.32 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.31, which suggests the price will decrease in the coming days. Percent R is at 44.13%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
